CFTR and cystic fibrosis: We conclude that ICM, as a sensitive CFTR biomarker for quantitative assessment of response to CFTR-directed therapeutics at the level of the CF basic defect, has a high potential to facilitate enhancement of personalized medicine for patients with common as well as rare CFTR genotypes.